Frank Wu

4.8k citations

39 papers · 2.0k · 1 hit paper · h-index 15

Impact in

Oncology top 2%
- Cutaneous Melanoma Detection and Management
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Molecular Biology top 5%
- Melanoma and MAPK Pathways
- PI3K/AKT/mTOR signaling in cancer

Papers in

Molecular Biology 19
- Melanoma and MAPK Pathways 5
Oncology 13
- Pancreatic and Hepatic Oncology Research 4

Co-authors: Mohammed Milhem (4 shared papers)Piotr Rutkowski (4 shared papers)Laurie Sherman (4 shared papers)Claus Garbe (4 shared papers)James Larkin (4 shared papers)Reinhard Dummer (4 shared papers)Peter Hersey (4 shared papers)Jochen Utikal (4 shared papers)
Journals: Journal of Clinical Oncology (9 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)Cancer Research (3 papers)Molecular Cancer Therapeutics (2 papers)Annals of Oncology (2 papers)
Partner nations: United States China France

In The Last Decade

Frank Wu

34 papers receiving 1.9k citations

Frank Wu's Hit Papers

align trajectories log scale

Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group 2012 · 1.1k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2012 Zurich Open Repository and Archive (University of Zurich)

Peers

Countries citing papers authored by Frank Wu

Since Specialization

Citations

This map shows the geographic impact of Frank Wu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Frank Wu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Frank Wu more than expected).

Fields of papers citing papers by Frank Wu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Frank Wu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Frank Wu. The network helps show where Frank Wu may publish in the future.

Co-authors

The 25 scholars most cited alongside Frank Wu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Frank Wu Line = papers co-authored together Frank Wu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 39 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Zurich Open Repository and Archive (University of Zurich) ·Keith T. Flaherty, Caroline Robert, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Brigitte Dréno, Michelle Casey, Laurie Sherman, Frank Wu, Dirk Schadendorf Hit paper breakdown →	2012	1071
2	A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC) Annals of Oncology ·George R. Blumenschein, Egbert F. Smit, David Planchard, Dongwook Kim, J. Cadranel, Tommaso De Pas, Frank Dunphy, Katalin Udud, Myung‐Ju Ahn, Nasser H. Hanna, Ji Hyun Kim, Julien Mazières, Sang Wan Kim, Paul Baas, Erica Rappold, Suman Redhu, A. Puski, Frank Wu, Pasi A. Jänne	2015	248
3	Activity of PXD101, a histone deacetylase inhibitor, in preclinical ovarian cancer studies Molecular Cancer Therapeutics ·Xiaozhong Qian, William J. LaRochelle, Gulshan Ara, Frank Wu, Kamille Dumong Petersen, Annemette Thougaard, Maxwell Sehested, Henri S. Lichenstein, Michael Jeffers	2006	117
4	The impact of endometrioma and laparoscopic cystectomy on serum anti-Müllerian hormone levels Reproductive Biology and Endocrinology ·Yuh‐Ming Hwu, Frank Wu, Sheng‐Hsiang Li, Fang‐Ju Sun, Ming-Huei Lin, Robert Kuo‐Kuang Lee	2011	96
5	Recombinant Human FIZZ3/Resistin Stimulates Lipolysis in Cultured Human Adipocytes, Mouse Adipose Explants, and Normal Mice Endocrinology ·Tatiana Ort, Anibal A. Arjona, John R. MacDougall, Pam J. Nelson, M.E. Rothenberg, Frank Wu, Andrew Eisen, Yuan‐Di C. Halvorsen	2005	63
6	Platelet-derived growth factor D: tumorigenicity in mice and dysregulated expression in human cancer. PubMed ·William J. LaRochelle, Michael Jeffers, José R. F. Corvalán, Xiao‐Chi Jia, Xiao Feng, Sandra Vanegas, Justin D. Vickroy, Xiaodong Yang, Francine Chen, Gadi Gazit, Jane Mayotte, Jennifer Macaluso, Beth Rittman, Frank Wu, Mohan Dhanabal, John L. Herrmann, Henri S. Lichenstein	2002	50
7	Discovery of an Orally Available Diazabicyclooctane Inhibitor (ETX0282) of Class A, C, and D Serine β-Lactamases Journal of Medicinal Chemistry ·Thomas F. Durand-Réville, Janelle Comita-Prevoir, Jing Zhang, Xiaoyun Wu, Tricia L. May‐Dracka, Jan Antoinette C. Romero, Frank Wu, April Chen, Adam B. Shapiro, Nicole Carter, Sarah M. McLeod, R.A. Giacobbe, Jeroen C. Verheijen, Sushmita D. Lahiri, M. Sacco, Yu Chen, John P. O’Donnell, Alita A. Miller, John P. Mueller, Rubén Tommasi	2020	49
8	Dual trigger with gonadotropin releasing hormone agonist and human chorionic gonadotropin significantly improves live birth rate for women with diminished ovarian reserve Reproductive Biology and Endocrinology ·Ming-Huei Lin, Frank Wu, Yuh‐Ming Hwu, Robert Kuo‐Kuang Lee, Ryh-Sheng Li, Sheng‐Hsiang Li	2019	41
9	Discovery of Imigliptin, a Novel Selective DPP-4 Inhibitor for the Treatment of Type 2 Diabetes ACS Medicinal Chemistry Letters ·Chutian Shu, Ge Hu, Michael Song, Jyun-hong Chen, Huimin Zhou, Qi Qu, Feng Wang, Xifeng Ma, Xiaolei Yang, Genyan Zhang, Yanwei Ding, Dapeng Zhou, Peng Peng, Cheng-Kon Shih, Jun Xu, Frank Wu	2014	32
10	DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Blood ·Suzanne Trudel, Randy Davis, Nicole Lewis, Kalpana Bakshi, Bikramjit Chopra, Rocío Montes de, Geraldine Ferron‐Brady, Laurie Eliason, Brandon E. Kremer, Ira Gupta, Frank Wu	2020	23
11	Substituted 2H-isoquinolin-1-ones as potent Rho-kinase inhibitors: Part 2, optimization for blood pressure reduction in spontaneously hypertensive rats Bioorganic & Medicinal Chemistry Letters ·John D. Ginn, Todd Bosanac, Rhonda Chen, Charles L. Cywin, Eugene R. Hickey, Mohammed A. Kashem, Steven Kerr, Stanley Kugler, Xiang Li, Anthony S. Prokopowicz, Sabine Schlyer, James D. Smith, Michael R. Turner, Frank Wu, Erick R. R. Young	2010	20
12	MEK114653: A randomized, multicenter, phase II study to assess efficacy and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant advanced non–small cell lung cancer (NSCLC). Journal of Clinical Oncology ·George R. Blumenschein, Egbert F. Smit, David Planchard, Dong‐Wan Kim, J. Cadranel, Tommaso De Pas, Frank Dunphy, Katalin Udud, Myung‐Ju Ahn, Nasser H. Hanna, Joo-Hang Kim, Julien Mazières, Sang‐We Kim, Paul Baas, Erica Rappold, Suman Redhu, Kevin M. Bellew, Michael Streit, Frank Wu, Pasi A. Jänne	2013	18
13	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS) compared with chemotherapy (C) in patients (pts) with BRAF_V600/kmutant advanced or metastatic melanoma (MM). Journal of Clinical Oncology ·Caroline Robert, Keith T. Flaherty, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Michelle Casey, Laurie Sherman, Wendy Crist, Frank Wu, Kiran Patel, Dirk Schadendorf	2012	18
14	Tinengotinib (TT-00420), a Novel Spectrum-Selective Small-Molecule Kinase Inhibitor, Is Highly Active Against Triple-Negative Breast Cancer Molecular Cancer Therapeutics ·Peng Peng, Xiaoyan Qiang, Guoyu Li, Lin Li, Shumao Ni, Qi Yu, Laura Sourd, Elisabetta Marangoni, Chao Hu, Dong Wang, Di Wu, Frank Wu	2022	17
15	Substituted 2H-isoquinolin-1-one as potent Rho-Kinase inhibitors. Part 1: Hit-to-lead account Bioorganic & Medicinal Chemistry Letters ·Frank Wu, Frank Büttner, Rhonda Chen, Eugene R. Hickey, Scott Jakes, Paul V. Kaplita, Mohammed A. Kashem, Steven Kerr, Stanley Kugler, Zofia Paw, Anthony S. Prokopowicz, Cheng-Kon Shih, Roger J. Snow, Erick R. R. Young, Charles L. Cywin	2010	15
16	Quantitative prediction of human pharmacokinetics and pharmacodynamics of imigliptin, a novel DPP-4 inhibitor, using allometric scaling, IVIVE and PK/PD modeling methods European Journal of Pharmaceutical Sciences ·Dongyang Liu, Xifeng Ma, Yang Liu, Huimin Zhou, Chongtie Shi, Frank Wu, Ji Jiang, Pei Hu	2016	14
17	First trimester ultrasound estimation of gestational age in pregnancies conceived after in vitro fertilization European Journal of Obstetrics & Gynecology and Reproductive Biology ·Frank Wu, Yuh‐Ming Hwu, Robert Kuo‐Kuang Lee, Sheng‐Hsiang Li, Fang‐Ju Sun, Ming-Huei Lin, S. Lin	2011	14
18	Efficacy and safety results of FGFR1-3 inhibitor, tinengotinib, as monotherapy in patients with advanced, metastatic cholangiocarcinoma: Results from phase II clinical trial. Journal of Clinical Oncology ·Milind Javle, Amit Mahipal, Lionel Aurelien Kankeu Fonkoua, Christos Fountzilas, Daneng Li, Meredith S. Pelster, Chih‐Yi Liao, Donald Richards, Dustin A. Deming, Mohamad Younes, Parvez Mantry, Allen Lee Cohn, Ed Kingsley, Jean Fan, Peng Peng, Caixia Sun, Hui Wang, Katie Hennessy, Y. Shan, Frank Wu	2024	9
19	In vitro and in vivo evaluation of O-alkyl derivatives of tramadol Bioorganic & Medicinal Chemistry Letters ·Liming Shao, Michael C. Hewitt, Thomas P. Jerussi, Frank Wu, Scott C. Malcolm, Paul Grover, Kevin Fang, Patrick Koch, Chris H. Senanayake, Nandkumar N. Bhongle, Seth Ribe, Roger P. Bakale, Mark G. Currie	2008	8
20	METRIC phase III study: Efficacy of trametinib (T), a potent and selective MEK inhibitor (MEKi), in progression-free survival (PFS) and overall survival (OS), compared with chemotherapy (C) in patients (pts) with BRAF_V600E/Kmutant advanced or metastatic melanoma (MM). Journal of Clinical Oncology ·Caroline Robert, Keith T. Flaherty, Peter Hersey, Paul Nathan, Claus Garbe, Mohammed Milhem, Lev Demidov, Jessica C. Hassel, Piotr Rutkowski, Peter G. Mohr, Reinhard Dummer, Uwe Trefzer, James Larkin, Jochen Utikal, Michelle Casey, Laurie Sherman, Wendy Crist, Frank Wu, Kiran Patel, Dirk Schadendorf	2012	8

About Frank Wu

Frank Wu is a scholar working on Molecular Biology, Oncology, Pulmonary and Respiratory Medicine, Surgery and Cell Biology, having authored 39 papers that have together received 2.0k indexed citations. Recurring topics across this work include Microtubule and mitosis dynamics (6 papers), Melanoma and MAPK Pathways (5 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (5 papers), Lung Cancer Treatments and Mutations (5 papers), Cancer Mechanisms and Therapy (4 papers), Pancreatic and Hepatic Oncology Research (4 papers), Advanced Breast Cancer Therapies (4 papers) and Cancer Genomics and Diagnostics (3 papers). The work is most often cited by research in Oncology (998 citations), Molecular Biology (1.3k citations), Reproductive Medicine (149 citations), Obstetrics and Gynecology (94 citations) and Cancer Research (169 citations). Frank Wu has collaborated with scholars based in United States, China and France. Frequent co-authors include Mohammed Milhem, Piotr Rutkowski, Laurie Sherman, Claus Garbe, James Larkin, Reinhard Dummer, Peter Hersey, Jochen Utikal, Michelle Casey and Dirk Schadendorf. Their work appears in journals such as Journal of Clinical Oncology, Bioorganic & Medicinal Chemistry Letters, Cancer Research, Molecular Cancer Therapeutics and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Frank Wu

Impact in

Papers in i

In The Last Decade

Frank Wu

Frank Wu's Hit Papers

Peers

Countries citing papers authored by Frank Wu

Fields of papers citing papers by Frank Wu

All Works

About Frank Wu

Explore authors with similar magnitude of impact

Papers in